AU2008324800B2 - Methods of treating scleroderma - Google Patents

Methods of treating scleroderma Download PDF

Info

Publication number
AU2008324800B2
AU2008324800B2 AU2008324800A AU2008324800A AU2008324800B2 AU 2008324800 B2 AU2008324800 B2 AU 2008324800B2 AU 2008324800 A AU2008324800 A AU 2008324800A AU 2008324800 A AU2008324800 A AU 2008324800A AU 2008324800 B2 AU2008324800 B2 AU 2008324800B2
Authority
AU
Australia
Prior art keywords
type
antibody
ifn
ifnar
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008324800A
Other languages
English (en)
Other versions
AU2008324800A1 (en
Inventor
Anthony Coyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2008324800A1 publication Critical patent/AU2008324800A1/en
Application granted granted Critical
Publication of AU2008324800B2 publication Critical patent/AU2008324800B2/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Request for Assignment Assignors: MEDIMMUNE, LLC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2008324800A 2007-11-05 2008-11-05 Methods of treating scleroderma Active AU2008324800B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99617507P 2007-11-05 2007-11-05
US60/996,175 2007-11-05
US10045408P 2008-09-26 2008-09-26
US61/100,454 2008-09-26
PCT/US2008/082481 WO2009061818A1 (en) 2007-11-05 2008-11-05 Methods of treating scleroderma

Publications (2)

Publication Number Publication Date
AU2008324800A1 AU2008324800A1 (en) 2009-05-14
AU2008324800B2 true AU2008324800B2 (en) 2014-03-27

Family

ID=43087976

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008324800A Active AU2008324800B2 (en) 2007-11-05 2008-11-05 Methods of treating scleroderma

Country Status (21)

Country Link
US (1) US20110008365A1 (enExample)
EP (1) EP2219452B1 (enExample)
JP (2) JP5767475B2 (enExample)
KR (1) KR20100098620A (enExample)
CN (1) CN101909444B (enExample)
AU (1) AU2008324800B2 (enExample)
BR (1) BRPI0819195A2 (enExample)
CA (1) CA2703705A1 (enExample)
CY (1) CY1117251T1 (enExample)
DK (1) DK2219452T3 (enExample)
ES (1) ES2557352T3 (enExample)
HR (1) HRP20151403T1 (enExample)
HU (1) HUE025787T2 (enExample)
IL (1) IL205452A (enExample)
MX (1) MX2010004814A (enExample)
NZ (1) NZ585064A (enExample)
PL (1) PL2219452T3 (enExample)
PT (1) PT2219452E (enExample)
RU (1) RU2530561C2 (enExample)
SI (1) SI2219452T1 (enExample)
WO (1) WO2009061818A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101952454B (zh) 2008-02-08 2014-06-04 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
WO2012162367A1 (en) * 2011-05-25 2012-11-29 Medimmune, Llc Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha
KR102185237B1 (ko) * 2012-06-13 2020-12-02 아스트라제네카 아베 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
CA3043823A1 (en) * 2015-11-17 2017-05-26 The Regents Of The University Of Colorado, A Body Corporate Novel multiplex assays to diagnose or evaluate diseases or disorders in mammals
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
CN118320101B (zh) * 2024-06-14 2024-09-17 天津嘉氏堂科技有限公司 iNOS抑制剂在制备治疗硬皮病胶原沉积药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333032B1 (en) * 1993-02-26 2001-12-25 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases
WO2007002096A2 (en) * 2005-06-22 2007-01-04 Genentech, Inc. Methods and compositions for targeting ifnar2
US20070092890A1 (en) * 2005-08-05 2007-04-26 Genentech, Inc. Methods and compositions for detecting autoimmune disorders

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3461808A (en) 1967-07-03 1969-08-19 Wood John Co Diaphragm hand pumps
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
DE3685996T2 (de) 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3923126A1 (de) 1989-07-13 1991-01-17 Stark Henric Lautsprecherbox
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US4997008A (en) 1990-04-26 1991-03-05 Moen Incorporated Faucet spout assembly
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
WO2003009740A2 (en) * 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
AU2002324727A1 (en) * 2001-08-17 2003-03-03 The Board Of Trustees Of The Leland Stanford Junior University Mammalian relaxin receptors
RU2318829C2 (ru) * 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
ES2399050T3 (es) 2003-12-10 2013-03-25 Medarex, Inc. Anticuerpos contra interferón alfa y sus usos
WO2005067963A1 (en) * 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
KR20150041193A (ko) * 2004-06-21 2015-04-15 메다렉스, 엘.엘.시. 인터페론 알파 수용체 1 항체 및 그의 용도
JP2010512315A (ja) 2006-12-06 2010-04-22 メディミューン，エルエルシー インターフェロンα誘導性薬力学的マーカー

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333032B1 (en) * 1993-02-26 2001-12-25 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases
WO2007002096A2 (en) * 2005-06-22 2007-01-04 Genentech, Inc. Methods and compositions for targeting ifnar2
US20070092890A1 (en) * 2005-08-05 2007-04-26 Genentech, Inc. Methods and compositions for detecting autoimmune disorders

Also Published As

Publication number Publication date
CN101909444A (zh) 2010-12-08
IL205452A (en) 2016-02-29
US20110008365A1 (en) 2011-01-13
IL205452A0 (en) 2010-12-30
JP2014144966A (ja) 2014-08-14
DK2219452T3 (en) 2016-01-11
ES2557352T3 (es) 2016-01-25
HRP20151403T1 (hr) 2016-02-12
KR20100098620A (ko) 2010-09-08
EP2219452A1 (en) 2010-08-25
RU2010122644A (ru) 2011-12-20
MX2010004814A (es) 2010-08-10
WO2009061818A1 (en) 2009-05-14
SI2219452T1 (sl) 2016-03-31
AU2008324800A1 (en) 2009-05-14
EP2219452A4 (en) 2012-05-02
PL2219452T3 (pl) 2016-04-29
CN101909444B (zh) 2013-09-18
PT2219452E (pt) 2016-01-26
CY1117251T1 (el) 2017-04-26
JP5767475B2 (ja) 2015-08-19
NZ585064A (en) 2012-08-31
EP2219452B1 (en) 2015-10-14
HK1151190A1 (zh) 2012-04-05
JP2011503008A (ja) 2011-01-27
HUE025787T2 (en) 2016-05-30
CA2703705A1 (en) 2009-05-14
BRPI0819195A2 (pt) 2017-05-23
RU2530561C2 (ru) 2014-10-10

Similar Documents

Publication Publication Date Title
US6245332B1 (en) Modulation of systemic memory T cell trafficking
JP5054977B2 (ja) Ｉｌ−１８結合タンパク質
Taylor Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases
US7939076B2 (en) Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist
AU2005277236A1 (en) Methods and compositions for treating allergic inflammation
JP6779621B2 (ja) ＭＡｄＣＡＭアンタゴニストの投与レジメン
TW202033558A (zh) 化膿性汗腺炎治療中使用的抗cd40抗體
EP2219452B1 (en) Methods of treating scleroderma
JP2012162552A (ja) 関節炎の全身処置のための組成物および方法
US20020054875A1 (en) Therapeutic methods that target fractalkine or CX3CR1
TW202106712A (zh) 類風溼性關節炎之診斷及治療方法
EP2193790A1 (en) IL-3 Inhibitors in use for treatment of rheumatoid arthritis in an early stage
US20050238643A1 (en) Modulation of lir function to treat rheumatoid arthritis
JP7495403B2 (ja) 巨細胞性動脈炎の治療
AU2002360376A1 (en) Modulation of LIR function to treat rheumatoid arthritis
HK1151190B (en) Methods of treating scleroderma
JP2002535376A (ja) Ｃｃｒ１アンタゴニストを用いた脱髄性炎症性疾患の治療方法
EP4052727A1 (en) Immune response suppressor

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 60/996,175 05 NOV 2007 US AND 61/100,454 26 SEP 2008 US

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ASTRAZENECA AB

Free format text: FORMER OWNER(S): MEDIMMUNE, LLC.